Single-dose darbepoetin administration to anemic preterm neonates

Journal of Perinatology

Volumn 25, Issue 11, 2005, Pages 725-730

  Warwood, Teresa L ^a   Ohls, Robin K ^c   Wiedmeier, Susan E ^b,d   Lambert, Diane K ^a   Jones, Cory ^a   Scoffield, Scott H ^a   Neeraj, Gupta ^e   Veng Pedersen, Peter ^e   Christensen, Robert D ^a  

^a McKay Dee Hospital Center   (United States)

^b LDS HOSPITAL   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; ERYTHROPOIESIS; FEMALE; GESTATIONAL AGE; HEMOGLOBIN DETERMINATION; HUMAN; INFANT; MALE; NEWBORN; NEWBORN INTENSIVE CARE; PHARMACODYNAMICS; PREMATURITY; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT;

ANEMIA, NEONATAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; ERYTHROPOIETIN; HALF-LIFE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; PILOT PROJECTS; PROSPECTIVE STUDIES; RETICULOCYTE COUNT;

EID: 27844567934     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211387     Document Type: Article

References (25)

1. Egrie JC, Dwyer E, Lykos M, et al. Novel erythropoiesis stimulating protein (NESP) has a longer plasma half-life and greater in vivo biological activity than recombinant human erythropoietin. Blood 1997;99:56a.
2. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl.):3-10.
3. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9.
4. www.aranesp.com.
5. Ohls RK, Dai A. The effect of Aranesp on the growth of fetal and neonatal erythroid progenitors. Blood 2003;102:18b.
6. Ohls RK, Dai A. Long-acting erythropoietin: Clinical studies and potential uses in neonates. Clin Perinatol 2004;31:77-89
7. Garcia MG, Hutson AD, Christensen RD. Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: A meta-analysis. J Perinatol 2002;22:108-11.
8. Christensen RD, Calhoun DA, Rimsza LM, et al. A consistent approach to procedures and practices in Neonatal Hematology. Clinics in Perinatol 2000;27:733-54.
9. Reiter PD, Rosenberg AA, Valuck RJ. Factors associated with successful epoetin alfa therapy in premature neonates. Ann Pharmacother 2000;34:433-9.
10. Reiter PD, Rosenberg AA, Valuck A, Novak K. Effect of short-term erythropoietin therapy in anemic premature neonates. J Perinatol 2005;25:125-9
11. Davis BH, Ornvold K, Bigelow NC. Flow cytometric reticulocyte maturity index: A useful laboratory parameter of erythropoietic activity in anemia. Cytometry 1995;22:35-9
12. Smith Jr RE, Tchekmedyian NS, Chan D, et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003;88:1851-8.
13. Kotasek D, Steger G, Faught W, et al. Aranesp 980291 Study Group. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34.
14. Lerner G, Kale AS, Warady BA, et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatri Nephrol 2002;17:933-7.
15. De Palo T, Giordano M, Poalumbo F, et al. Clinical experience with darbepoetin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 2004;19:337-40.
16. Donato H, Vain N, Rendo P, et al. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants; results of a randomized, placebo-controlled, multicenter trial. Pediatrics 2000;105:1066-72.
17. Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams of less. A randomized, double blind, placebo-controlled study. J Pediatr 1997;131:661-5.
18. Ohls RK, Veerman MW, Christensen RD. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in parenteral nutrition. J Pediatr 1996;128:518-23.
19. Meyer MP, Meyer JH, Commerford A, et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity; results of a double blind, placebo-controlled study. Pediatrics 1994;93:918-23.
20. Maier RF, Obladen M, Kattner E, et al. High-versus low-dose erythropoietin in extremely low birth weight infants. The European multicentere rhEpo study group. J Pediatr 1998;132:866-70.
21. Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res 1998;28:1-11.
22. Lesesve JF, Lacombe F, Marit G, Bernard P, Belloc F, Reiffers J. High fluorescence reticulocytes are an indicator of bone marrow recovery after chemotherapy. Eur J Haematol 1995;54:61-3.
23. Olds RK. Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity. Paediatr Drugs 2002;4:111-21.
24. Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW. Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993;21:635-42.
25. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5.